Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

B Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data…
posteditor
posteditor
Articles: 16137

Other News